-- Israel Stocks: Teva, D-Pharm, Can Fite, Partner, Cellcom, Camtek
-- B y   S h o s h a n n a   S o l o m o n
-- 2012-02-22T12:21:54Z
-- http://www.bloomberg.com/news/2012-02-22/israel-stocks-teva-d-pharm-can-fite-partner-cellcom-camtek.html
Israel ’s  TA-25 index  declined for
the first time in four days, sliding 0.1 percent to 1,118.62 at
1:40 p.m. in  Tel Aviv .  The following stocks rose or fell today. Symbols are in
parentheses.  Camtek Ltd. (CAMT)  (CAMT IT) tumbled 8.3 percent, the most since
Oct. 4, to 8.705 shekels, bringing the company’s two day drop to
11 percent. The maker of optical-inspection systems reported a
fourth-quarter loss yesterday.  D-Pharm Ltd. (DPRM)   rallied 31 percent, the biggest
intraday jump since Bloomberg started tracking the shares in
August 2009, to 1.261 shekels. The biopharmaceutical company
said it is considering the acquisition of Thrombotech Ltd. which
is developing a peptide that improves the efficiency of stroke
medication.  Can Fite Biopharma Ltd. (CFBI)   advanced 7.4 percent to
0.478 shekel. The biopharmaceutical company said its CF102 drug
for the treatment of primary  liver cancer  received orphan drug
status from the U.S. Food and Drug Administration. Ophthalix
Inc., a unit, received a patent in China.  Habas H.Z. Investments (1960) Ltd. (HBS)   advanced 3.1
percent, the most since Feb. 12, to 5.30 shekels. The investment
and holding company said it received early commitments from
institutions for about 54.5 million shekels ($15 million) in a
tender to extend its series four bonds.  Partner Communications Co. (PTNR)   slumped 4.6 percent,
the biggest intraday decline since Jan. 29, to 30.05 shekels.
Israel’s second-largest mobile-phone company postponed final
results until the end of March and forecast a drop in fourth-
quarter profit.  Cellcom Israel Ltd. (CEL)  , the country’s
biggest mobile-phone company, fell 3.5 percent to 52.50 shekels,
the lowest close on record.  Teva Pharmaceutical Industries Ltd. (TEVA)   advanced 1
percent to 167.60 shekels, or the equivalent of $44.71. The
U.S.-traded shares of the world’s largest maker of generic drugs
jumped 1.3 percent to $45.24 in  New York  yesterday.  To contact the reporter on this story:
Shoshanna Solomon in Tel Aviv at 
 ssolomon22@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  